Skip to main content

Table 1 Baseline demographic and disease characteristics of ITT patient population

From: Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study

Characteristic Result (n = 162)
Demographics  
 Age, years 37.4 ± 9.8
Sex  
 Male, n (%) 40 (24.7 %)
 Female, n (%) 122 (75.3 %)
Race  
 Caucasian, n (%) 153 (94.4 %)
 Black, n (%) 2 (1.2 %)
 Asian, n (%) 2 (1.2 %)
 Other, n (%) 5 (3.1 %)
 Education, total years completed 14.9 ± 3.3
Disease characteristics  
 MS classification  
  Relapsing-remitting, n (%) 156 (96.3 %)
  Secondary progressive, n (%) 6 (3.7 %)
  Months since onset of MS symptoms 53.3 ± 76.1
  Months since MS diagnosis 24.0 ± 57.6
  Months since last relapse 6.4 ± 9.5
Number of relapses since onset of MS symptoms, n (%)  
 0 6 (3.7 %)
 1 44 (27.2 %)
 2 55 (34.0 %)
 3 34 (21.0 %)
 4 12 (7.4 %)
 ≥5 11 (6.8 %)
 Expanded disability status scale (EDSS) Score 1.8 ± 1.3
Cognitive function  
 Symbol digit modalities test (SDMT) 51.0 ± 13.1
 Patients failing test, n (%) 35 (22.9 %)
Selective reminding test (SRT)  
 Long-term storage 41.8 ± 15.5
 Patients failing test, n (%) 61 (40.4 %)
 Consistent long-term retrieval 30.0 ± 15.8
 Patients failing test, n (%) 59 (39.1 %)
3-second paced auditory serial addition test (PASAT) 42.8 ± 11.4
 Patients failing test, n (%) 47 (31.3 %)
Cognitively impaired (failing ≥2 of the above tests) 67 (47.8 %)
  1. Data presented as mean ± standard deviation except as indicated
  2. ITT intent-to-treat, MS multiple sclerosis